These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 15390078

  • 1. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
    Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R.
    Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
    [Abstract] [Full Text] [Related]

  • 2. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [Abstract] [Full Text] [Related]

  • 3. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA, Lupu R.
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [Abstract] [Full Text] [Related]

  • 4. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis.
    Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R.
    Int J Oncol; 2004 Jun; 24(6):1369-83. PubMed ID: 15138577
    [Abstract] [Full Text] [Related]

  • 5. Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene.
    Menendez JA, Vellon L, Oza BP, Lupu R.
    J Cell Biochem; 2005 Apr 01; 94(5):857-63. PubMed ID: 15669079
    [Abstract] [Full Text] [Related]

  • 6. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA, Vellon L, Lupu R.
    Int J Mol Med; 2006 Dec 01; 18(6):1081-7. PubMed ID: 17089011
    [Abstract] [Full Text] [Related]

  • 7. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA, Vellon L, Lupu R.
    Med Hypotheses; 2005 Dec 01; 64(5):997-1001. PubMed ID: 15780499
    [Abstract] [Full Text] [Related]

  • 8. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Menendez JA, Colomer R, Lupu R.
    Med Hypotheses; 2005 Dec 01; 64(2):342-9. PubMed ID: 15607569
    [Abstract] [Full Text] [Related]

  • 9. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.
    Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP.
    Oncogene; 2005 Jan 06; 24(1):39-46. PubMed ID: 15489885
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells.
    Menendez JA, Oza BP, Atlas E, Verma VA, Mehmi I, Lupu R.
    Oncogene; 2004 Jun 17; 23(28):4945-58. PubMed ID: 15094777
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A, Colomer R, Brunet J, Menendez JA.
    Int J Oncol; 2007 Oct 17; 31(4):769-76. PubMed ID: 17786307
    [Abstract] [Full Text] [Related]

  • 12. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
    Weng MS, Ho CT, Ho YS, Lin JK.
    Toxicol Appl Pharmacol; 2007 Jan 15; 218(2):107-18. PubMed ID: 17182072
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere).
    Menendez JA, Lupu R, Colomer R.
    Breast Cancer Res Treat; 2004 Mar 15; 84(2):183-95. PubMed ID: 14999148
    [Abstract] [Full Text] [Related]

  • 14. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA, Vellon L, Lupu R.
    Ann Oncol; 2005 Aug 15; 16(8):1253-67. PubMed ID: 15870086
    [Abstract] [Full Text] [Related]

  • 15. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
    Pan MH, Lin CC, Lin JK, Chen WJ.
    J Agric Food Chem; 2007 Jun 27; 55(13):5030-7. PubMed ID: 17539658
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis.
    Menendez JA, Colomer R, Lupu R.
    Med Hypotheses; 2005 Jun 27; 64(2):337-41. PubMed ID: 15607568
    [Abstract] [Full Text] [Related]

  • 17. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
    Menendez JA, Oza BP, Colomer R, Lupu R.
    Int J Oncol; 2005 Jun 27; 26(6):1507-15. PubMed ID: 15870863
    [Abstract] [Full Text] [Related]

  • 18. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast.
    Sastre-Garau X, Genin P, Rousseau A, Al Ghuzlan A, Nicolas A, Fréneaux P, Rosty C, Sigal-Zafrani B, Couturier J, Thiery JP, Magdelénat H, Vincent-Salomon A.
    Histopathology; 2004 Aug 27; 45(2):142-7. PubMed ID: 15279632
    [Abstract] [Full Text] [Related]

  • 19. The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of Her-2/neu-driven breast cancer.
    Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE.
    Cancer Res; 2007 Feb 01; 67(3):1105-12. PubMed ID: 17283144
    [Abstract] [Full Text] [Related]

  • 20. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
    Schiffer IB, Gebhard S, Heimerdinger CK, Heling A, Hast J, Wollscheid U, Seliger B, Tanner B, Gilbert S, Beckers T, Baasner S, Brenner W, Spangenberg C, Prawitt D, Trost T, Schreiber WG, Zabel B, Thelen M, Lehr HA, Oesch F, Hengstler JG.
    Cancer Res; 2003 Nov 01; 63(21):7221-31. PubMed ID: 14612517
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.